Zynex Inc. (ZYXI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Zynex, Inc. (ZYXI) Q3 2025 Earnings Call Prepared Remarks Transcript
Zynex, Inc. ( ZYXI ) Q3 2025 Earnings Call November 18, 2025 9:00 AM EST Company Participants Vikram Bajaj - Chief Financial Officer Steven Dyson - CEO & Director Presentation Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Zynex Third Quarter 2025 Earnings Conference Call.
Zynex taps adviser Province, forms special board committee to review strategic options
Zynex Inc (NASDAQ:ZYXI) said on Friday it has hired financial advisory firm Province LLC and formed a special board committee to evaluate a range of strategic alternatives. The company said Province will assist in reviewing options that include potential capital-raising, recapitalization and restructuring strategies.
Zynex welcomes Steve Dyson as CEO, adds to leadership team
Zynex Inc (NASDAQ:ZYXI), a medical technology company specializing in non-invasive devices for pain management, rehabilitation, and patient monitoring, announced the arrival of Steven Dyson as its new CEO, along with the appointment of several senior leaders. The company announced back in June that Dyson had been selected as incoming CEO.
Zynex, Inc. (ZYXI) Q2 2025 Earnings Call Transcript
Zynex, Inc. (NASDAQ:ZYXI ) Q2 2025 Earnings Conference Call July 31, 2025 4:15 PM ET Company Participants Anna Lucsok - Chief Operating Officer Daniel J. Moorhead - Chief Financial Officer Donald Gregg - President of Zynex Monitoring Solutions Thomas Sandgaard - Founder, President, CEO & Chairman Conference Call Participants Jeffrey Scott Cohen - Ladenburg Thalmann & Co. Inc., Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Operator Good afternoon, ladies and gentlemen, and welcome to the Zynex Second Quarter 2025 Earnings Conference Call.
Zynex Inc. (ZYXI) Reports Q2 Loss, Misses Revenue Estimates
Zynex Inc. (ZYXI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to earnings of $0.04 per share a year ago.
Zynex eyes growth revival under new CEO, advances oximeter technology
Zynex Inc (NASDAQ:ZYXI), a developer of non-invasive medical devices, is laying the foundation for a return to growth following a pivotal second quarter marked by leadership changes, operational streamlining, and a key FDA submission for its next-generation pulse oximeter. The company appointed industry veteran Steven Dyson as CEO in Q2, a move founder Thomas Sandgaard called “transformational” for the Colorado-based firm.
Zynex: New CEO Steven Dyson shares his vision – ICYMI
Zynex Inc (NASDAQ:ZYXI) earlier this week outlined changes to its leadership as Thomas Sandgaard prepares to move into the chairman role. The company said Steven Dyson will step in as the new chief executive officer.
Zynex CEO Thomas Sandgaard discusses leadership transition - ICYMI
Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard talked with Proactive about his decision to step down from his position after nearly three decades leading the medical device company. He described the challenges of starting a company with no funding, navigating public listings, and expanding operations to help over a million patients manage pain.
Zynex awarded UK patent for non-invasive sepsis monitoring technology
Zynex Inc (NASDAQ:ZYXI) announced that it has been issued a UK patent for its multiparameter, non-invasive sepsis monitor. The company highlighted that its patented technology is designed to continuously track multiple physiological signals with the goal of providing early alerts on patient trends and potential sepsis development.
Zynex, Inc. (ZYXI) Q1 2025 Earnings Call Transcript
Zynex, Inc. (NASDAQ:ZYXI ) Q1 2025 Earnings Conference Call April 29, 2025 4:15 PM ET Company Participants Brian Prenoveau - IR Thomas Sandgaard - Chairman, President and CEO Dan Moorhead - CFO Anna Lucsok - COO Don Greg - President of Zynex Monitoring Solutions Conference Call Participants Shagun Singh - RBC Capital Markets Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Zynex First Quarter 2025 Earnings Conference Call.
Zynex Inc. (ZYXI) Reports Q1 Loss, Lags Revenue Estimates
Zynex Inc. (ZYXI) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to break-even earnings per share a year ago.
Zynex CEO eyes new growth as company pushes forward with product expansion
Zynex Inc (NASDAQ:ZYXI) is looking to new product launches and tighter cost controls to drive growth in 2025, as CEO Thomas Sandgaard said the company is positioning itself for long-term expansion despite a challenging start to the year. “We expect to complete our FDA submission for our NiCO laser pulse oximeter in the next couple of weeks, which we believe can be a significant driver of new customers, revenue streams and will diversify our product offering,” Sandgaard said in a statement accompanying its first quarter results.
